Viewing data from:

NIKKI

ANDA

DROSPIRENONE; ETHINYL ESTRADIOL | A201661 | LUPIN LTD

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: YAZ(TE code: AB)

Hatch-Waxman Litigation

1 case on OB patents from PACER

Case	Court	Filed	Status	Judge
Bayer Schering Pharma AG et al v. Lupin Ltd et al 2:2010cv01166 ANDA 201661drospirenone and ethinylestradiol	NVD	2010-07-15	Terminated 2013-11-27	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Medicare Part D Spending

CMS annual spending data for Nikki (2023)

Total Spending

$172K

Total Claims

3,378

Beneficiaries

979

Avg Cost/Unit

$0.90

Spending Trend

$197K(2019)→$198K(2020)→$199K(2021)→$210K(2022)→$172K(2023)

YoY Change:-6.0%

5yr CAGR:-7.2%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (1)

#001 — 3MG;0.02MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: May 27, 2014

No patent or exclusivity listings for this strength.